Aileron Therapeutics, Inc. (ALRN)
| Market Cap | 97.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.38M |
| Shares Out | 90.33M |
| EPS (ttm) | -0.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $1.06 |
| Previous Close | $1.17 |
| Change ($) | -0.11 |
| Change (%) | -9.40% |
| Day's Open | 1.19 |
| Day's Range | 1.02 - 1.20 |
| Day's Volume | 1,543,185 |
| 52-Week Range | 0.64 - 2.47 |
-- Several existing Aileron investors, including Satter Medical Technology Partners and Lincoln Park Capital Fund, LLC, also participated in the offering -- – Aileron plans to use net proceeds to under...
WATERTOWN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors for th...
As with many biopharma names, there's volatility and risk in ALRN stock. This firm is seeking to reduce the effects of chemotherapy.
WATERTOWN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the third quarter ended September 30, 2020.
WATERTOWN, Mass., Oct. 24, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced new positive clinical data from its ongoing Phase 1b trial demonstrating clinical proof of concept...
WATERTOWN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that it will host a conference call and live webcast to discuss results from a Phase 1b proof-of-c...
Aileron Therapeutics (ALRN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that proof-of-concept data from the company’s Phase 1b study of ALRN-6924 will be featured in a la...
WATERTOWN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $...
WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate pr...
Here we discuss five biotech companies recording impressive growth so far in 2020.
WATERTOWN, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the second quarter ended June 30, 2020.
WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two u...
WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today that it has completed enrollment in the dose optimization expansion cohort of its ongoing open-la...
-- Novel approach leverages the ability of intracellular p53 protein to induce cell cycle arrest in healthy cells to prevent severe toxicities driven by chemotherapy’s off-target effects -- – In p5...
WATERTOWN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the closing of its underwritten public offering of its common stock, including the exercise by t...
WATERTOWN, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a publ...
WATERTOWN, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Aileron als...
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
WATERTOWN, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical t...
Enrollment completed in the dose optimization part of the ongoing Phase 1b/2 clinical trial of ALRN-6924 as a chemoprotection agent in cancer patients - - - Scheduled to report interim results from ...
Presentation of interim results from the dose-optimization part of the Phase 1b myelopreservation study - - - Final data readout from Phase 1b for both dose optimization and schedule optimization in...
WATERTOWN, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion o...
Aileron Therapeutics, Inc. (ALRN) CEO Manuel Aivado on Q3 2019 Results - Earnings Call Transcript
Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy
Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy.
Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer.
Final data expected in the second quarter of 2020 Final data expected in the second quarter of 2020
WATERTOWN, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, today ...
WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseas...
About ALRN
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in pa... [Read more...]
| Industry Biotechnology | IPO Date Jun 29, 2017 |
| Stock Exchange NASDAQ | Ticker Symbol ALRN |
Analyst Forecasts
According to 3 analysts, the average rating for ALRN stock is "Strong Buy." The 12-month stock price forecast is 3.50, which is an increase of 230.19% from the latest price.